TW202237580A - Pde4降解劑、醫藥組合物及治療應用 - Google Patents
Pde4降解劑、醫藥組合物及治療應用 Download PDFInfo
- Publication number
- TW202237580A TW202237580A TW110146590A TW110146590A TW202237580A TW 202237580 A TW202237580 A TW 202237580A TW 110146590 A TW110146590 A TW 110146590A TW 110146590 A TW110146590 A TW 110146590A TW 202237580 A TW202237580 A TW 202237580A
- Authority
- TW
- Taiwan
- Prior art keywords
- mixtures
- tautomers
- compound
- mirror
- ethoxy
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 claims abstract 154
- 238000000034 method Methods 0.000 claims abstract 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract 6
- 201000010099 disease Diseases 0.000 claims abstract 3
- 208000035475 disorder Diseases 0.000 claims abstract 3
- 208000024891 symptom Diseases 0.000 claims abstract 3
- 230000001404 mediated effect Effects 0.000 claims abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract 2
- 239000000203 mixture Substances 0.000 claims 240
- -1 cycloalkane radical Chemical class 0.000 claims 82
- 230000000155 isotopic effect Effects 0.000 claims 69
- 125000000217 alkyl group Chemical group 0.000 claims 66
- 125000003118 aryl group Chemical group 0.000 claims 52
- 229910052739 hydrogen Inorganic materials 0.000 claims 52
- 239000001257 hydrogen Substances 0.000 claims 52
- 125000001072 heteroaryl group Chemical group 0.000 claims 51
- 125000000623 heterocyclic group Chemical group 0.000 claims 50
- 150000003839 salts Chemical class 0.000 claims 49
- 239000000651 prodrug Substances 0.000 claims 48
- 229940002612 prodrug Drugs 0.000 claims 48
- 239000012453 solvate Substances 0.000 claims 48
- 150000004677 hydrates Chemical class 0.000 claims 46
- KXDAEFPNCMNJSK-UHFFFAOYSA-N Benzamide Chemical compound NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 claims 44
- 125000006376 (C3-C10) cycloalkyl group Chemical group 0.000 claims 36
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 35
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 claims 33
- 229910052805 deuterium Inorganic materials 0.000 claims 33
- 125000001424 substituent group Chemical group 0.000 claims 32
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims 31
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims 30
- 125000003710 aryl alkyl group Chemical group 0.000 claims 30
- DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 claims 29
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 24
- 125000006716 (C1-C6) heteroalkyl group Chemical group 0.000 claims 23
- 125000005843 halogen group Chemical group 0.000 claims 20
- RWTNPBWLLIMQHL-UHFFFAOYSA-N fexofenadine Chemical group C1=CC(C(C)(C(O)=O)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 RWTNPBWLLIMQHL-UHFFFAOYSA-N 0.000 claims 19
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 19
- 125000002947 alkylene group Chemical group 0.000 claims 17
- 150000002431 hydrogen Chemical class 0.000 claims 16
- 125000000753 cycloalkyl group Chemical group 0.000 claims 15
- 125000004474 heteroalkylene group Chemical group 0.000 claims 15
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 15
- 125000004093 cyano group Chemical group *C#N 0.000 claims 14
- 125000004404 heteroalkyl group Chemical group 0.000 claims 13
- 125000003342 alkenyl group Chemical group 0.000 claims 12
- 125000000304 alkynyl group Chemical group 0.000 claims 12
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 12
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 12
- 125000003161 (C1-C6) alkylene group Chemical group 0.000 claims 10
- 125000001462 1-pyrrolyl group Chemical group [*]N1C([H])=C([H])C([H])=C1[H] 0.000 claims 10
- 125000002993 cycloalkylene group Chemical group 0.000 claims 9
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 claims 8
- 239000003446 ligand Substances 0.000 claims 8
- 229910052760 oxygen Inorganic materials 0.000 claims 8
- 239000001301 oxygen Substances 0.000 claims 8
- 101100296720 Dictyostelium discoideum Pde4 gene Proteins 0.000 claims 7
- 101100082610 Plasmodium falciparum (isolate 3D7) PDEdelta gene Proteins 0.000 claims 7
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 claims 7
- QLNJFJADRCOGBJ-UHFFFAOYSA-N propionamide Chemical compound CCC(N)=O QLNJFJADRCOGBJ-UHFFFAOYSA-N 0.000 claims 7
- 125000006649 (C2-C20) alkynyl group Chemical group 0.000 claims 6
- 150000001408 amides Chemical class 0.000 claims 6
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 6
- 229910052736 halogen Inorganic materials 0.000 claims 6
- 150000002367 halogens Chemical class 0.000 claims 6
- 229940080818 propionamide Drugs 0.000 claims 6
- 125000003358 C2-C20 alkenyl group Chemical group 0.000 claims 4
- 125000004450 alkenylene group Chemical group 0.000 claims 4
- 125000004419 alkynylene group Chemical group 0.000 claims 4
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 4
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 claims 4
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 4
- LTHCSWBWNVGEFE-UHFFFAOYSA-N octanamide Chemical compound CCCCCCCC(N)=O LTHCSWBWNVGEFE-UHFFFAOYSA-N 0.000 claims 4
- 125000006586 (C3-C10) cycloalkylene group Chemical group 0.000 claims 3
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 claims 3
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 claims 3
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 3
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims 3
- ILRSCQWREDREME-UHFFFAOYSA-N dodecanamide Chemical compound CCCCCCCCCCCC(N)=O ILRSCQWREDREME-UHFFFAOYSA-N 0.000 claims 3
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 claims 3
- 208000027866 inflammatory disease Diseases 0.000 claims 3
- GHLZUHZBBNDWHW-UHFFFAOYSA-N nonanamide Chemical compound CCCCCCCCC(N)=O GHLZUHZBBNDWHW-UHFFFAOYSA-N 0.000 claims 3
- 125000001400 nonyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims 3
- 125000004482 piperidin-4-yl group Chemical group N1CCC(CC1)* 0.000 claims 3
- 125000004214 1-pyrrolidinyl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 claims 2
- ARYAZKDNTNIEOP-BEBVUIBBSA-N 4-amino-6-[12-[3-[(2,6-dioxopiperidin-3-yl)amino]anilino]dodecyl]-2-[(1S)-1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]isoindole-1,3-dione Chemical compound CCOC(C=C([C@@H](CS(C)(=O)=O)N(C(C1=CC(CCCCCCCCCCCCNC2=CC(NC(CCC(N3)=O)C3=O)=CC=C2)=CC(N)=C11)=O)C1=O)C=C1)=C1OC ARYAZKDNTNIEOP-BEBVUIBBSA-N 0.000 claims 2
- 108091007065 BIRCs Proteins 0.000 claims 2
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims 2
- DXFDXFUZWWUFFA-UHFFFAOYSA-N ClC=1C=NC=C(C=1NC(C1=CC(=C(C=C1)OC(F)F)OCCCN1CCC(CC1)C1=C2CN(C(C2=CC(=C1)F)=O)C1C(NC(CC1)=O)=O)=O)Cl Chemical compound ClC=1C=NC=C(C=1NC(C1=CC(=C(C=C1)OC(F)F)OCCCN1CCC(CC1)C1=C2CN(C(C2=CC(=C1)F)=O)C1C(NC(CC1)=O)=O)=O)Cl DXFDXFUZWWUFFA-UHFFFAOYSA-N 0.000 claims 2
- SNRUBQQJIBEYMU-UHFFFAOYSA-N Dodecane Natural products CCCCCCCCCCCC SNRUBQQJIBEYMU-UHFFFAOYSA-N 0.000 claims 2
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims 2
- 102000055031 Inhibitor of Apoptosis Proteins Human genes 0.000 claims 2
- SCXLPDILVIXDQU-UHFFFAOYSA-N N-(3,5-dichloropyridin-4-yl)-4-(difluoromethoxy)-3-[2-[4-[2-(2,6-dioxopiperidin-3-yl)-6-fluoro-1-oxo-3H-isoindol-5-yl]piperidin-1-yl]ethoxy]benzamide Chemical compound O=C(C(C=C1)=CC(OCCN(CC2)CCC2C(C=C(CN(C(CCC(N2)=O)C2=O)C2=O)C2=C2)=C2F)=C1OC(F)F)NC(C(Cl)=CN=C1)=C1Cl SCXLPDILVIXDQU-UHFFFAOYSA-N 0.000 claims 2
- 102000006275 Ubiquitin-Protein Ligases Human genes 0.000 claims 2
- 108010083111 Ubiquitin-Protein Ligases Proteins 0.000 claims 2
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 claims 2
- 150000001335 aliphatic alkanes Chemical class 0.000 claims 2
- 229910052801 chlorine Inorganic materials 0.000 claims 2
- 239000000460 chlorine Substances 0.000 claims 2
- 125000002704 decyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims 2
- FTZSDHHWPWGCDI-UHFFFAOYSA-N dodecanediamide Chemical compound NC(=O)CCCCCCCCCCC(N)=O FTZSDHHWPWGCDI-UHFFFAOYSA-N 0.000 claims 2
- 229910052731 fluorine Inorganic materials 0.000 claims 2
- 239000011737 fluorine Substances 0.000 claims 2
- 125000003187 heptyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 2
- 125000001841 imino group Chemical group [H]N=* 0.000 claims 2
- 125000005647 linker group Chemical group 0.000 claims 2
- NFVUAUVSFDFOJT-UHFFFAOYSA-N octanediamide Chemical compound NC(=O)CCCCCCC(N)=O NFVUAUVSFDFOJT-UHFFFAOYSA-N 0.000 claims 2
- IBBMAWULFFBRKK-UHFFFAOYSA-N picolinamide Chemical compound NC(=O)C1=CC=CC=N1 IBBMAWULFFBRKK-UHFFFAOYSA-N 0.000 claims 2
- 125000000587 piperidin-1-yl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 claims 2
- 125000003386 piperidinyl group Chemical group 0.000 claims 2
- 150000003254 radicals Chemical class 0.000 claims 2
- 238000006467 substitution reaction Methods 0.000 claims 2
- QMHIMXFNBOYPND-UHFFFAOYSA-N 4MTO Natural products CC1=CSC=N1 QMHIMXFNBOYPND-UHFFFAOYSA-N 0.000 claims 1
- 206010002556 Ankylosing Spondylitis Diseases 0.000 claims 1
- 208000027496 Behcet disease Diseases 0.000 claims 1
- JGLMVXWAHNTPRF-CMDGGOBGSA-N CCN1N=C(C)C=C1C(=O)NC1=NC2=CC(=CC(OC)=C2N1C\C=C\CN1C(NC(=O)C2=CC(C)=NN2CC)=NC2=CC(=CC(OCCCN3CCOCC3)=C12)C(N)=O)C(N)=O Chemical compound CCN1N=C(C)C=C1C(=O)NC1=NC2=CC(=CC(OC)=C2N1C\C=C\CN1C(NC(=O)C2=CC(C)=NN2CC)=NC2=CC(=CC(OCCCN3CCOCC3)=C12)C(N)=O)C(N)=O JGLMVXWAHNTPRF-CMDGGOBGSA-N 0.000 claims 1
- 208000017667 Chronic Disease Diseases 0.000 claims 1
- 206010012438 Dermatitis atopic Diseases 0.000 claims 1
- 206010012442 Dermatitis contact Diseases 0.000 claims 1
- 102000012199 E3 ubiquitin-protein ligase Mdm2 Human genes 0.000 claims 1
- 108050002772 E3 ubiquitin-protein ligase Mdm2 Proteins 0.000 claims 1
- 101000988419 Homo sapiens cAMP-specific 3',5'-cyclic phosphodiesterase 4D Proteins 0.000 claims 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 1
- IMJAVZDZCOZXOZ-UHFFFAOYSA-N O=C1CCC(NC2=CC=CC=C2)C(=O)N1 Chemical compound O=C1CCC(NC2=CC=CC=C2)C(=O)N1 IMJAVZDZCOZXOZ-UHFFFAOYSA-N 0.000 claims 1
- 208000011623 Obstructive Lung disease Diseases 0.000 claims 1
- YZCKVEUIGOORGS-IGMARMGPSA-N Protium Chemical compound [1H] YZCKVEUIGOORGS-IGMARMGPSA-N 0.000 claims 1
- 201000004681 Psoriasis Diseases 0.000 claims 1
- 201000001263 Psoriatic Arthritis Diseases 0.000 claims 1
- 208000036824 Psoriatic arthropathy Diseases 0.000 claims 1
- 150000001336 alkenes Chemical class 0.000 claims 1
- 206010003246 arthritis Diseases 0.000 claims 1
- 201000008937 atopic dermatitis Diseases 0.000 claims 1
- 125000004106 butoxy group Chemical group [*]OC([H])([H])C([H])([H])C(C([H])([H])[H])([H])[H] 0.000 claims 1
- 102100029170 cAMP-specific 3',5'-cyclic phosphodiesterase 4D Human genes 0.000 claims 1
- 230000015556 catabolic process Effects 0.000 claims 1
- 230000001684 chronic effect Effects 0.000 claims 1
- 208000010247 contact dermatitis Diseases 0.000 claims 1
- VDBXLXRWMYNMHL-UHFFFAOYSA-N decanediamide Chemical compound NC(=O)CCCCCCCCC(N)=O VDBXLXRWMYNMHL-UHFFFAOYSA-N 0.000 claims 1
- 238000006731 degradation reaction Methods 0.000 claims 1
- 125000003438 dodecyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- ZHNUHDYFZUAESO-UHFFFAOYSA-N formamide Substances NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 claims 1
- 125000001245 hexylamino group Chemical group [H]N([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C(C([H])([H])[H])([H])[H] 0.000 claims 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 1
- 230000001939 inductive effect Effects 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- TVMXDCGIABBOFY-UHFFFAOYSA-N octane Chemical compound CCCCCCCC TVMXDCGIABBOFY-UHFFFAOYSA-N 0.000 claims 1
- 201000008482 osteoarthritis Diseases 0.000 claims 1
- 101150032584 oxy-4 gene Proteins 0.000 claims 1
- AEABQBMUYZBBCW-UHFFFAOYSA-N pentanamide Chemical compound CC[CH]CC(N)=O AEABQBMUYZBBCW-UHFFFAOYSA-N 0.000 claims 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 claims 1
- 125000002572 propoxy group Chemical group [*]OC([H])([H])C(C([H])([H])[H])([H])[H] 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 238000003419 tautomerization reaction Methods 0.000 claims 1
- GBXQPDCOMJJCMJ-UHFFFAOYSA-M trimethyl-[6-(trimethylazaniumyl)hexyl]azanium;bromide Chemical compound [Br-].C[N+](C)(C)CCCCCC[N+](C)(C)C GBXQPDCOMJJCMJ-UHFFFAOYSA-M 0.000 claims 1
- MSYGAHOHLUJIKV-UHFFFAOYSA-N 3,5-dimethyl-1-(3-nitrophenyl)-1h-pyrazole-4-carboxylic acid ethyl ester Chemical compound CC1=C(C(=O)OCC)C(C)=NN1C1=CC=CC([N+]([O-])=O)=C1 MSYGAHOHLUJIKV-UHFFFAOYSA-N 0.000 abstract 3
- 102000011017 Type 4 Cyclic Nucleotide Phosphodiesterases Human genes 0.000 abstract 3
- 108010037584 Type 4 Cyclic Nucleotide Phosphodiesterases Proteins 0.000 abstract 3
- 239000001064 degrader Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06008—Dipeptides with the first amino acid being neutral
- C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
- C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Rheumatology (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pulmonology (AREA)
- Physical Education & Sports Medicine (AREA)
- Pain & Pain Management (AREA)
- Dermatology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063124877P | 2020-12-14 | 2020-12-14 | |
| US63/124,877 | 2020-12-14 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| TW202237580A true TW202237580A (zh) | 2022-10-01 |
Family
ID=79288082
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW110146590A TW202237580A (zh) | 2020-12-14 | 2021-12-13 | Pde4降解劑、醫藥組合物及治療應用 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20240124418A1 (https=) |
| EP (1) | EP4259621A1 (https=) |
| JP (1) | JP2024500377A (https=) |
| KR (1) | KR20230157936A (https=) |
| CN (1) | CN117203196A (https=) |
| AU (1) | AU2021402911A1 (https=) |
| CA (1) | CA3201965A1 (https=) |
| IL (1) | IL303611A (https=) |
| TW (1) | TW202237580A (https=) |
| WO (1) | WO2022132603A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2021119571A1 (en) * | 2019-12-12 | 2021-06-17 | Biotheryx, Inc. | Pde4 inhibitors, pharmaceutical compositions, and therapeutic applications |
| WO2024168096A2 (en) * | 2023-02-07 | 2024-08-15 | Biotheryx, Inc. | Pde4 degraders, pharmaceutical compositions, and therapeutic applications |
| US20240327381A1 (en) * | 2023-02-08 | 2024-10-03 | Celgene Corporation | Compounds and Compositions for Selective Degradation of Engineered Proteins |
| AU2024323358A1 (en) * | 2023-08-17 | 2026-02-26 | Katalytic Therapeutics, Inc. | Pde4 protein degraders, pharmaceutical compositions, and therapeutic applications |
Family Cites Families (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4410545A (en) | 1981-02-13 | 1983-10-18 | Syntex (U.S.A.) Inc. | Carbonate diester solutions of PGE-type compounds |
| US4328245A (en) | 1981-02-13 | 1982-05-04 | Syntex (U.S.A.) Inc. | Carbonate diester solutions of PGE-type compounds |
| US4409239A (en) | 1982-01-21 | 1983-10-11 | Syntex (U.S.A.) Inc. | Propylene glycol diester solutions of PGE-type compounds |
| US5052558A (en) | 1987-12-23 | 1991-10-01 | Entravision, Inc. | Packaged pharmaceutical product |
| US5612059A (en) | 1988-08-30 | 1997-03-18 | Pfizer Inc. | Use of asymmetric membranes in delivery devices |
| US5055252A (en) | 1989-01-12 | 1991-10-08 | Superior Walls Of America, Ltd. | Method of constructing an integrated concrete wall structure |
| US5585112A (en) | 1989-12-22 | 1996-12-17 | Imarx Pharmaceutical Corp. | Method of preparing gas and gaseous precursor-filled microspheres |
| IT1246382B (it) | 1990-04-17 | 1994-11-18 | Eurand Int | Metodo per la cessione mirata e controllata di farmaci nell'intestino e particolarmente nel colon |
| US5543390A (en) | 1990-11-01 | 1996-08-06 | State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University | Covalent microparticle-drug conjugates for biological targeting |
| GB9212693D0 (en) * | 1992-06-15 | 1992-07-29 | Celltech Ltd | Chemical compounds |
| ES2102036T3 (es) * | 1992-06-15 | 1997-07-16 | Celltech Therapeutics Ltd | Derivados con grupo fenilo trisustituido utilizados como inhibidores selectivos de la fosfodiesterasa iv. |
| US6274552B1 (en) | 1993-03-18 | 2001-08-14 | Cytimmune Sciences, Inc. | Composition and method for delivery of biologically-active factors |
| US5523092A (en) | 1993-04-14 | 1996-06-04 | Emory University | Device for local drug delivery and methods for using the same |
| US5985307A (en) | 1993-04-14 | 1999-11-16 | Emory University | Device and method for non-occlusive localized drug delivery |
| US6004534A (en) | 1993-07-23 | 1999-12-21 | Massachusetts Institute Of Technology | Targeted polymerized liposomes for improved drug delivery |
| US5759542A (en) | 1994-08-05 | 1998-06-02 | New England Deaconess Hospital Corporation | Compositions and methods for the delivery of drugs by platelets for the treatment of cardiovascular and other diseases |
| US5660854A (en) | 1994-11-28 | 1997-08-26 | Haynes; Duncan H | Drug releasing surgical implant or dressing material |
| US5525907A (en) | 1995-03-17 | 1996-06-11 | Hughes Missile Systems Company | Active impulse magnetometer with bipolar magnetic impulse generator and fast fourier transform receiver to detect sub-surface metallic materials |
| US6316652B1 (en) | 1995-06-06 | 2001-11-13 | Kosta Steliou | Drug mitochondrial targeting agents |
| US5798119A (en) | 1995-06-13 | 1998-08-25 | S. C. Johnson & Son, Inc. | Osmotic-delivery devices having vapor-permeable coatings |
| US6039975A (en) | 1995-10-17 | 2000-03-21 | Hoffman-La Roche Inc. | Colon targeted delivery system |
| TW345603B (en) | 1996-05-29 | 1998-11-21 | Gmundner Fertigteile Gmbh | A noise control device for tracks |
| JP2000508339A (ja) | 1996-10-01 | 2000-07-04 | シーマ・ラブス・インコーポレイテッド | 味隠蔽マイクロカプセル組成物及び製造方法 |
| US6131570A (en) | 1998-06-30 | 2000-10-17 | Aradigm Corporation | Temperature controlling device for aerosol drug delivery |
| US6120751A (en) | 1997-03-21 | 2000-09-19 | Imarx Pharmaceutical Corp. | Charged lipids and uses for the same |
| US6060082A (en) | 1997-04-18 | 2000-05-09 | Massachusetts Institute Of Technology | Polymerized liposomes targeted to M cells and useful for oral or mucosal drug delivery |
| US6350458B1 (en) | 1998-02-10 | 2002-02-26 | Generex Pharmaceuticals Incorporated | Mixed micellar drug deliver system and method of preparation |
| US6048736A (en) | 1998-04-29 | 2000-04-11 | Kosak; Kenneth M. | Cyclodextrin polymers for carrying and releasing drugs |
| US6020358A (en) * | 1998-10-30 | 2000-02-01 | Celgene Corporation | Substituted phenethylsulfones and method of reducing TNFα levels |
| US6271359B1 (en) | 1999-04-14 | 2001-08-07 | Musc Foundation For Research Development | Tissue-specific and pathogen-specific toxic agents and ribozymes |
| US6667316B1 (en) * | 1999-11-12 | 2003-12-23 | Celgene Corporation | Pharmaceutically active isoindoline derivatives |
| BR0113626A (pt) | 2000-08-30 | 2003-06-17 | Pfizer Prod Inc | Formulações de liberação sustentada para secretores de hormÈnio do crescimento |
| US6962940B2 (en) * | 2002-03-20 | 2005-11-08 | Celgene Corporation | (+)-2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione: methods of using and compositions thereof |
| RU2738833C9 (ru) * | 2014-04-14 | 2022-02-28 | Арвинас, Оперэйшнз, Инк. | Имидные модуляторы протеолиза и способы их применения |
| WO2017201069A1 (en) | 2016-05-18 | 2017-11-23 | Biotheryx, Inc. | Oxoindoline derivatives as protein function modulators |
| US10040804B2 (en) | 2016-12-21 | 2018-08-07 | Biotheryx, Inc. | Compounds targeting proteins, compositions, methods, and uses thereof |
| US10406165B2 (en) | 2017-03-14 | 2019-09-10 | Biotheryx, Inc. | Compounds targeting proteins, compositions, methods, and uses thereof |
| US10513515B2 (en) | 2017-08-25 | 2019-12-24 | Biotheryx, Inc. | Ether compounds and uses thereof |
| WO2019173224A1 (en) | 2018-03-05 | 2019-09-12 | Biotheryx, Inc. | Deuterated compounds and chimeras and uses thereof |
| CA3094988A1 (en) | 2018-03-30 | 2019-10-03 | Biotheryx, Inc. | Thienopyrimidinone compounds |
| WO2019241271A1 (en) | 2018-06-13 | 2019-12-19 | Biotheryx, Inc. | Fused thiophene compounds |
| WO2020102195A1 (en) | 2018-11-13 | 2020-05-22 | Biotheryx, Inc. | Substituted isoindolinones |
| CN113453681B (zh) | 2018-12-19 | 2024-10-11 | 细胞基因公司 | 经取代的3-((3-氨基苯基)氨基)哌啶-2，6-二酮化合物、其组合物及使用它们的治疗方法 |
| JP2022533260A (ja) | 2019-05-24 | 2022-07-21 | バイオセリックス， インコーポレイテッド | タンパク質を標的とする化合物及びその医薬組成物並びにそれらの治療的応用 |
| WO2021119571A1 (en) * | 2019-12-12 | 2021-06-17 | Biotheryx, Inc. | Pde4 inhibitors, pharmaceutical compositions, and therapeutic applications |
-
2021
- 2021-12-13 CN CN202180093639.7A patent/CN117203196A/zh active Pending
- 2021-12-13 CA CA3201965A patent/CA3201965A1/en active Pending
- 2021-12-13 EP EP21840310.3A patent/EP4259621A1/en active Pending
- 2021-12-13 AU AU2021402911A patent/AU2021402911A1/en active Pending
- 2021-12-13 IL IL303611A patent/IL303611A/en unknown
- 2021-12-13 US US18/256,636 patent/US20240124418A1/en active Pending
- 2021-12-13 JP JP2023535990A patent/JP2024500377A/ja active Pending
- 2021-12-13 WO PCT/US2021/062995 patent/WO2022132603A1/en not_active Ceased
- 2021-12-13 TW TW110146590A patent/TW202237580A/zh unknown
- 2021-12-13 KR KR1020237023788A patent/KR20230157936A/ko active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2024500377A (ja) | 2024-01-09 |
| KR20230157936A (ko) | 2023-11-17 |
| IL303611A (en) | 2023-08-01 |
| WO2022132603A1 (en) | 2022-06-23 |
| US20240124418A1 (en) | 2024-04-18 |
| CN117203196A (zh) | 2023-12-08 |
| EP4259621A1 (en) | 2023-10-18 |
| AU2021402911A1 (en) | 2023-07-06 |
| CA3201965A1 (en) | 2022-06-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20240025863A1 (en) | Sos1 protein degraders, pharmaceutical compositions thereof, and their therapeutic applications | |
| CA2972148C (en) | Benzazepine dicarboxamide compounds | |
| TW202237580A (zh) | Pde4降解劑、醫藥組合物及治療應用 | |
| EP4355741B1 (en) | Sos1 protein degraders, pharmaceutical compositions thereof, and their therapeutic applications | |
| TW202231269A (zh) | Kras蛋白降解劑、其醫藥組合物及其治療應用 | |
| JP7447080B2 (ja) | Ｐａｄ４阻害剤としての置換チエノピロール | |
| TWI902711B (zh) | 用於治療ｐｄ-ｌ１疾病之雜芳基-聯苯基醯胺 | |
| JP7483678B2 (ja) | Ｐａｄ４阻害剤としての置換ベンズイミダゾール | |
| JP7434281B2 (ja) | Ｐａｄ酵素のベンズイミダゾール阻害剤 | |
| TW202019415A (zh) | Pad酶之吲哚及氮雜吲哚抑制劑 | |
| US20240368121A1 (en) | Estrogen receptor degraders, pharmaceutical compositions thereof, and their therapeutic applications | |
| US20240190883A1 (en) | Kras protein degraders, pharmaceutical compositions thereof, and their therapeutic applications | |
| US20240190885A1 (en) | Kras protein degraders, pharmaceutical compositions thereof, and their therapeutic applications | |
| US20250186434A1 (en) | Sos1 protein degraders, pharmaceutical compositions thereof, and their therapeutic applications | |
| KR20200130287A (ko) | 헤테로아릴 화합물, 이의 약학 조성물 및 이의 치료적 용도 | |
| KR20240168922A (ko) | 방향족 헤테로사이클릭 화합물, 그의 제조 방법 및 그의 용도 | |
| WO2024123967A1 (en) | Sarm1 inhibitors, pharmaceutical compositions, and therapeutic applications | |
| WO2023185920A1 (en) | Fak degraders, pharmaceutical compositions, and therapeutic applications | |
| US12419962B2 (en) | Quinazolines, pharmaceutical compositions, and therapeutic applications | |
| WO2025038987A2 (en) | Pde4 protein degraders, pharmaceutical compositions, and therapeutic applications | |
| WO2024168096A2 (en) | Pde4 degraders, pharmaceutical compositions, and therapeutic applications | |
| US12570687B2 (en) | Triterpenoid compounds, pharmaceutical compositions thereof, and their use for treating a nuclear receptor subfamily 4 group a member 1-mediated disease |